“Generic Vascepa remains a key product driving FY22 US revenue. View Full Image Catching paceThe delay in approval of Sputnik V vaccine, too, had been keeping Street sentiments soft. Dr Reddy’s had partnered with Russian Direct Investment Fund to conduct clinical trials of the Sputnik V vaccine and signed the rights for distribution in India. Catalysts, as per Nomura, include a higher-than-estimated contribution from product-specific opportunities like generic Revlimid in Canada and US, generic Vascepa in the US, Sputnik V and better-than-expected growth prospects in India, APIs and emerging markets. Meanwhile the company’s prospects in India remain strong and the acquisition of Wockhardt portfolio (25-30% growth in last two quarters) is driving domestic growth.

Source: Mint March 22, 2021 23:48 UTC